Artificial intelligence is enabling personalized cancer vaccines and rare-disease treatments, with Moderna and Merck reporting a 'landmark moment' in a melanoma vaccine trial involving 1,100 patients,…
Moderna and Merck announced that their personalized mRNA cancer vaccine, Intismeran Autogene, combined with the immunotherapy Keytruda, reduced the risk of melanoma recurrence by 49% within five years…
On August 15, Anthropic CEO Dario Amodei argued that AI companies will earn trust by curing diseases, and the past week showcased advances in AI-driven medicine, including Moderna and Merck's INTerpat…
A Stanford study found that debate-based multi-agent architectures outperform other team strategies in complex reasoning tasks, but single agents often match or exceed their performance when given equ…
Moderna and Merck's experimental mRNA cancer vaccine intismeran autogene met its primary endpoint of recurrence-free survival and a key secondary endpoint in a Phase 3 trial of 1,137 patients with res…
Merck and Moderna announced positive topline Phase 3 results for their personalized cancer treatment INTerpath-001, which uses AI to identify up to 34 neoantigens per patient and an mRNA vaccine to ta…
Billionaire entrepreneur Mark Cuban said on X that doctors should help patients configure AI tools such as Claude, ChatGPT, Gemini, and Grok for their treatment, arguing that AI will replace most doct…
Tempus AI's $1.5 billion acquisition of Personalis, announced July 20, 2026, looks prescient after Moderna and Merck reported positive Phase 3 results for mRNA-4157, a personalized cancer vaccine that…
Pathos AI, a New York City-based AI-driven drug development company, agreed to license the experimental breast cancer drug JSKN016 from China's Jiangsu Alphamab Biopharmaceutical for an upfront paymen…
LG CNS announced on July 27 that it joined CuspAI's AI Materials Foundry as a founding member and Korean delivery partner, a 48-member consortium that includes Nvidia, Meta, AMD, 3M, and Merck. LG CNS…
LG CNS has joined the founding members of the AI Materials Foundry, a global alliance using AI to accelerate new materials discovery, becoming the only Korean IT company in the initiative. The allianc…
Synthesia launched Roleplay Sessions on July 22, a product that lets employees practice conversations with AI avatars that provide real-time feedback and scoring, moving beyond static training videos.…
Tempus AI has agreed to acquire Personalis, Inc. for $1.5 billion, or $16.25 per share, gaining its NeXT Personal minimal residual disease blood test for cancer detection. The deal targets a $20 billi…
Databricks announced the expansion of Agent Bricks into a comprehensive agent platform at the Data + AI Summit 2026, with over 100,000 agents built and 1+ quadrillion tokens processed annually. The pl…
Knowledge graphs are emerging as the accountability layer for high-stakes AI systems in pharma, law, insurance, and defense, enabling traceability and reducing failures. Examples include China's Syste…